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Autosomal-dominant polycystic kidney disease (ADPKD) is
characterized by numerous fluid-filled kidney cysts. Net fluid
secretion into renal cysts is caused by transepithelial
transport mediated by the apical cystic fibrosis
transmembrane conductance regulator chloride channel,
which leads to cyst enlargement. Here we found that
forskolin, a potent adenylyl cyclase agonist, stimulated anion
secretion by monolayers of kidney cells derived from patients
with ADPKD. TRAM-34, a specific KCa3.1 potassium channel
blocker, inhibited this current, and in vitro cyst formation and
enlargement by the cells cultured within a collagen gel. Net
chloride secretion was enhanced by the KCa3.1 activator
DCEBIO and both chloride secretion and in vitro cyst growth
were inhibited by overexpression of myotubularin-related
protein-6, a phosphatase that specifically inhibits KCa3.1
channel activity. Our study suggests that KCa3.1 channels
play a critical role in transcellular chloride secretion and net
fluid transport into the kidney cysts of patients with ADPKD
by maintaining the electrochemical driving force for chloride
efflux through apical chloride channels. Pharmacological
inhibitors of KCa3.1 channels may provide a novel and
effective therapy to delay progression to kidney failure in
patients with ADPKD.
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Autosomal-dominant polycystic kidney disease (ADPKD) is
one of the most common monogenetic causes of kidney
disease and is caused by mutations in one of the two genes,
PKD1 or PKD2, which encode for the gene products
polycystin PC1 and PC2, respectively. Cyst formation is
believed to involve a two-step mechanism.1–3 First, the loss of
PC1 or PC2 in the mutant cells causes a loss of cell polarity,
leading to a de-differentiated and proliferative cellular
phenotype. The resulting increase in proliferation of renal
epithelia cells then initiates the outgrowth of renal cysts.
Second, once cysts form, increased secretion of Cl into the
cyst lumen provides the driving force for the progressive
enlargement of cysts by stimulating the movement of Naþ
and water into the cyst lumen. Replacement of normal renal
parenchyma with cysts results in the loss of renal function,
often leading to renal failure requiring dialysis or transplant.
Although the mechanisms whereby the loss of PC1 and
PC2 lead to disease are not yet fully understood, studies over
the past several years have begun to shed light on this process.
Recent evidence has indicated that increased levels of cAMP
in mutant renal epithelia plays an important role in the
pathogenesis of ADPKD and contributes to both transe-
pithelial secretion of fluid and proliferation of cyst epi-
thelia.4–6 For example, cAMP activates apical Cl channels
leading to the stimulation of Cl secretion into the cyst
lumen. Apical Cl secretion then functions to drive the
transepithelial movement of Naþ and water into the cyst
lumen resulting in cyst growth. The major apical Cl channel
in ADPKD renal epithelia is the cystic fibrosis transduction
regulator (CFTR), which has led to the proposition that
pharmacological inhibitors of the CFTR may be used
therapeutically to slow progression of disease in patients with
ADPKD.7–10 In support of this hypothesis, some studies have
suggested that the coexistence of a mutation in the CFTR
channel in patients with ADPKD leads to a reduced disease
severity.9–11 cAMP, via activation of the RAS–MAP kinase
pathway, also contributes to the proliferation of ADPKD
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mutant renal epithelia.6,12 Pathways other than cAMP are also
important for the increase in proliferation seen in ADPKD.
For example, loss of PC1 leads to the activation of mTor,
Stats, and cyclin-dependent kinases, all of which contribute to
the increase in proliferation of mutant renal epithelia.13–16
In addition to being directly activated via cAMP and
protein kinase A, apical Cl secretion by the CFTR in
bronchial and colonic epithelia has also been shown to be
indirectly regulated by a potassium channel, KCa3.1 (also
known as SK4, KCNN4, and IKCa2þ ).17–20 By mediating the
efflux of Kþ , KCa3.1 channels function to maintain a
relatively negative intracellular membrane potential, which is
required to maintain the electrochemical driving force for
apical Cl secretion by the CFTR. KCa3.1 channels are also
activated by cAMP and PKA, and thus some of the signaling
pathways that mediate the activation of KCa3.1 channel
activity are active in ADPKD cyst lining epithelia.21,22
In the current study, we found that KCa3.1 channels play a
critical role in apical Cl secretion by ADPKD cyst epithelia
and that pharmacologic inhibition of KCa3.1 blocks cyst
formation in vitro. Although a number of CFTR blockers are
under development, safe and potent CFTR blockers do not
yet exist. These findings when taken together suggest that
pharmacological inhibitors of KCa3.1, which are already in
phase 3 studies in humans in sickle cell disease, may be useful
to slow progression of kidney disease patients with ADPKD.
RESULTS
MDCK, NHK, and ADPKD epithelial cells express KCa3.1
channels
To begin to address whether KCa3.1 channels play a role in
Cl secretion by renal epithelia, we determined whether
KCa3.1 mRNA was expressed in madine darby canine kidney
(MDCK) cells, primary cultures of normal human kidney
epithelial cells (NHK cells), or in cells isolated from renal
cysts of ADPKD patients (ADPKD cells). We found that all
three cells express KCa3.1 mRNA (Figure 1a). In addition,
whole-cell patch clamp experiments demonstrated KCa3.1
channel activity in MDCK, NHK, and ADPKD cells (Figure 1c,
g, and h). The current was demonstrated to be KCa3.1 based
on its dependence on Caþ (Figure 1b), inhibition by the
KCa3.1-specific inhibitor TRAM-34 (triaryl methane) with an
EC50 of 50 nM (Figure 1f),
23,24 inhibition by an siRNA to
TRAM-34 (Figure 1d, activation by the direct KCa3.1 activator
EBIO (see Figure 5), and its reversal potential of 70 mV,
which is predicted from the extracellular Kþ concentration.
KCa3.1 channels have previously been shown to be
activated by cAMP.21,22 To address whether cAMP also
activates KCa3.1 channels in renal epithelia, MDCK cells
were stimulated with forskolin/3-isobutyl-1-methylxanthine
(IBMX) and KCa3.1 channel activity was determined.
Treatment with forskolin/IBMX led to about a twofold
increase in KCa3.1 channel activity (Figure 1c and e). These
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Figure 1 | MDCK, NHK, and ADPKD cells express KCa3.1. (a) Total RNA was isolated from MDCK, NHK, and ADPKD cells, reverse
transcribed into cDNA, and amplified with primers specific to KCa3.1. Shown is an ethidium bromide stained gel of the amplified PCR
products. (b–f) To characterize KCa3.1 current in MDCK cells whole-cell patch clamp experiments were performed on MDCK cells as
described below. Shown is the representative trace of current–voltage (I–V) plot with (b) zero or (c) 1 mM free calcium in the pipette (N¼ 8).
This current was increased by the application of Fsk/IBMX and inhibited by TRAM-34. (d) Representative I–V trace of KCa3.1 current
from siRNA KCa3.1-transfected MDCK cells. (e) Summary data from panels c and d. (f) Dose response of TRAM-34 in MDCK cells (N¼ 4).
(g) Representative I–V trace of KCa3.1 from (g) NHK and (h) ADPKD cells (N¼ 4 each) before and after treatment with 100 nM TRAM-34.
These cells also express some BK current.
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findings indicate that cAMP, in addition to activating the
CFTR, also activates KCa3.1.
Forskolin-stimulated Cl secretion by the CFTR in MDCK,
NHK, and ADPKD cells is inhibited by the specific KCa3.1
channel inhibitor TRAM-34
Forskolin/IBMX, by increasing intracellular cAMP levels,
has been previously shown to stimulate chloride secretion
in renal epithelia.8 Forskolin/IBMX-stimulated chloride
secretion was measured in renal epithelia using an Ussing
Chamber as described previously.8 Treatment of the apical
membrane of MDCK cells with forskolin/IBMX-stimulated
Cl transport across the MDCK monolayer (Figure 2a and b).
The addition of bumetanide, an inhibitor of the NKCC1
co-transporter, to forskolin/IBMX-stimulated cells inhibited
ICl, indicating that the current being measured is Cl
 (Figure
2a and b). To determine whether KCa3.1 is required for Cl
secretion, we tested whether TRAM-34 blocked forskolin/
IBMX-stimulated ICl; TRAM-34 has previously been shown
to be a specific inhibitor of KCa3.1 channels.23,24 TRAM-34
markedly attenuated forskolin/IBMX-stimulated ICl when
added after (Figure 2a) or before (Figure 2b) the treatment
with forskolin/IBMX.
To determine whether KCa3.1 is also critical for Cl
secretion by primary human renal epithelia, we assessed
whether TRAM-34 inhibited ICl in NHK and ADPKD cells.
TRAM-34 also inhibited forskolin/IBMX-stimulated ICl in both
normal and ADPKD cells by more than 80%, although ADPKD
cells required a slightly higher concentration of TRAM-34 to
completely inhibit ICl (Figure 3a–c). Charybdotoxin, another
KCa3.1 channel inhibitor, also markedly attenuated forskolin/
IBMX-stimulated ICl in all three cell types (data not shown).
KCa3.1 is believed to stimulate Cl secretion by maintain-
ing a negative membrane potential (EM), which functions to
provide a favorable electrochemical driving force to drive
apical Cl secretion by the CFTR.17,18 EM was measured in
ADPKD cells before and after the treatment of forskolin/IBMX
in the presence or absence of TRAM-34 using the fluorescent
probe DiBAC4(3).
25 Hyperpolarization of cells leads to the
accumulation of DiBAC4(3) in cell membranes, leading to a
decrease in emitted fluorescence in the cell. We found that
treatment of ADPKD cells with forskolin/IBMX led to the
hyperpolarization of ADPKD cells as determined by a decrease
in emitted fluorescent (Figure 3d and f). Consistent with the
idea that KCa3.1 channels play a critical role in hyperpolarizing
ADPKD cells, we found that the decrease in emitted fluores-
cent intensity stimulated by forskolin/IBMX was markedly
inhibited by the treatment with TRAM-34 (Figure 3e). Thus,
in agreement with the results in Figure 1, this data suggest that
cAMP indirectly activates KCa3.1, which results in the efflux of
Kþ from ADPKD cells and the hyperpolarization of the cell.
The increase in negative membrane potential then provides a
favorable electrochemical gradient to drive apical Cl secretion
by the CFTR.
TRAM-34 does not directly inhibit the CFTR or apical
Cl channels
Previous studies have demonstrated that the CFTR is the
primary channel that mediates apical Cl secretion in
MDCK, NHK and ADPKD cells used in these studies.7,26
At the concentrations used, TRAM-34 has been shown to be a
specific inhibitor of KCa3.1,23,24 and thus it is unlikely that
TRAM-34 inhibits ICl by directly blocking the CFTR or other
apical Cl channels. Nevertheless, to confirm that TRAM-34
does not inhibit ICl via a direct effect on the CFTR channel,
we determined if ICl was inhibited by TRAM-34 in MDCK
cells in which the basolateral membrane was permeabilized
by nystatin. Permeabilization of the basolateral membrane
should eliminate the requirement for KCa3.1 for apical Cl
secretion. We found that the addition of TRAM-34 to either
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Figure 2 | TRAM-34 inhibits ICl in MDCK cells. MDCK cells were
seeded directly onto permeable filter supports and studied, and
then mounted in a modified Ussing chambers on average 10 days
after plating. Short circuit chloride current (ICl) was then
determined after stimulation with forskolin/IBMX in the presence
of amiloride (Amil) (100 mM) and 4,40-diisothiocyanostilbene
disulphonic acid (DIDS) (100 mM). To determine whether TRAM-34
inhibits forskolin/IBMX-stimulated ICl, MDCK cells were treated
with TRAM-34 (1 mM) either after (a) or before (b) stimulation with
forskolin/IBMX. Plotted is the ICl that was normalized to the stable
forskolin/IBMX-stimulated current (n¼ 10 experiments per point).
In panel a, forskolin/IBMX stimulated ICl to 9.58±0.6 mA. This
stimulated current was inhibited by TRAM-34 to 1.6±0.08 mA and
by bumetanide to 0.4±0.08 mA. In panel b, forskolin/IBMX-
stimulated ICl current of 10±0.27 mA was inhibited by bumetanide
to 2.5±0.14mA, whereas in TRAM-34 pretreated cells, forskolin/
IBMX could not activate ICl and there was no significant difference
before (0.75±0.25 mA) and after (0.66±0.33 mA) bumetanide
treatment. Currents were recorded after 10–15 min of TRAM-34 or
bumetanide application. Bumetanide of 100 mM was used, which
blocks basolateral entry of Cl into cells, indicating the current
being measured is Cl.
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the apical or basolateral membrane did not inhibit ICl in
MDCK cells in which the basolateral membrane was
pretreated with nystatin (Figure 4). In contrast, the addition
of 100 mM of the specific CFTR inhibitor diphenylamine-2-
carboxylic acid (DPC) to the apical membrane led to a
marked inhibition of ICl. These findings indicate that TRAM-
34 inhibits ICl by indirectly blocking apical Cl
 secretion,
which is consistent with its known effect to inhibit KCa3.1.
DCEBIO, a direct activator of KCa3.1, stimulates Cl secretion
in ADPKD cells
5,6-Dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one
(DCEBIO) has been shown to directly activate KCa3.1.27
To confirm that KCa3.1 plays a critical role in apical
Cl secretion as well as to assess whether direct activation
of KCa3.1 by cAMP can independently stimulate ICl,
we determined whether the addition of DCEBIO to
ADPKD cells stimulated ICl. The addition of DCEBIO
alone (without forskolin/IBMX) stimulated ICl in ADPKD
cells (Figure 5a and b). Moreover, the increase in ICl was
markedly attenuated by the treatment with TRAM-34.
Thus, these findings indicate that signals that directly
activate KCa3.1 can independently contribute to apical
Cl secretion in ADPKD cells, presumably by mediating
the hyperpolarization of the membrane potential as demon-
strated in Figure 3d.
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Figure 3 | TRAM-34 inhibits ICl in NHK and ADPKD cells. (a) NHK or (b) ADPKD cells were seeded directly onto permeable filter supports,
and short circuit chloride current (ICl) was measured after stimulation with forskolin/IBMX as described in Figure 2. After a stable current was
achieved, cells were then treated sequentially with 2 and 5 mM TRAM-34. Plotted are the ICl that was normalized to the stable forskolin/IBMX-
stimulated current (representative trace of seven experiments). (c) Summary of data in panels a and b (n¼ 7 per experiments). Currents
were recorded after 10–15 min of TRAM-34 or bumetanide application. (d) EM was measured using the fluorescent dye DiBAC4(3). ADPKD
cells were loaded with DiBAC4(3) and EM was measured before and after stimulation with forskolin/IBMX by measuring the emitted
fluorescence above 520 nm following excitation at 488 nm. (d) Forskolin/IBMX treatment led to hyperplarization of the cell membrane
potential as shown by a decrease in the fluorescence. (e) Treatment with TRAM-34 1 mM markedly inhibited the Forskolin/IBMX-stimulated
decrease in fluorescence. (f) Summary of data from 30 to 40 cells with different interventions as indicated on the y axis.
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TRAM-34 inhibits cyst formation by MDCK, NHK, and
ADPKD cells in collagen matrix
MDCK, NHK, and ADPKD cells seeded in a collagen gel
matrix form cysts in cell culture after stimulation with
forskolin, which is dependent on apical Cl secretion by the
CFTR. We found that treatment with TRAM-34 also
inhibited the formation of cysts in collagen by MDCK cells
(Figure 6). Treatment with TRAM-34 inhibited further
growth of cysts by MDCK cells if added after 6 days of
stimulation with forskolin when cysts were just beginning to
form (Figure 6b, d, and e). The inhibition by TRAM-34 was
of similar magnitude to glibencalmide, a CFTR inhibitor that
has previously been shown to inhibit cyst formation by
MDCK cells (Figure 6c and e).8
To investigate the role of KCa3.1 in fluid secretion by
human ADPKD cyst epithelia cells, we tested the effect of
TRAM-34 on cyst formation by cultured ADPKD cells grown
in a collagen matrix. Consistent with the inhibition of Cl
secretion by TRAM-34 in these cells (Figure 3), we found that
TRAM-34 also inhibited cyst formation in ADPKD cells
(Figure 7a and b).
Overexpression of the PI(3)P phosphatase
myotubularin-related protein 6 inhibited Cl secretion
and cyst growth in MDCK cells
We have previously shown that KCa3.1 requires PI(3)P for
activity and is specifically inhibited by MTMR6.29–32 Thus, if
KCa3.1 is important for cyst formation, we would expect that
the overexpression of MTMR6 wild type (WT), but not a
MTMR6 phosphatase dead (PD), to inhibit cyst formation
and Cl secretion. We generated stable pools of MDCK cells
that overexpress MTMR6(WT) and MTMR6(PD) using
lentiviral constructs as previously described.30 We found
that MTMR6(WT), but not MTMR6(PD), inhibited ICl and
formation of cysts in collagen (Figure 8a and b).
TRAM-34 does not inhibit proliferation of ADPKD cells
KCa3.1 has been found to play an important role in
proliferation of a number of cells including T and B
lymphocytes and vascular smooth muscle cells.30,33,34 To
assess whether KCa31.1 plays a role in proliferation of NHK
or ADPKD cells, proliferation of these cells was assessed after
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Figure 4 | TRAM-34 does not inhibit ICl in MDCK cells in which
the basolateral membrane is permeabilized with nystatin. ICl
was measured in MDCK cell monolayers in which the basolateral
membrane was permeabilized with nystatin (0.36 mg ml1).
(a) A representative trace in which after stimulation with forskolin/
IBMX, cells were treated with TRAM-34 (5 mM) followed by
treatment with the CFTR inhibitor diphenylamine-2-carboxylic
acid (DPC) (100 mM). (b) Summary data showing the effect of
TRAM-34 and DPC on forskolin/IBMX-stimulated ICl current. Short
circuit ICl was inhibited by DPC but not by TRAM-34 (N¼ 4).
Currents were recorded after 10–15 min of TRAM-34 or DPC
application. These findings indicate that TRAM-34 does not
directly block the CFTR channel.
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Figure 5 | DECBIO, a direct activator or KCa3.1, stimulates ICl
in ADPKD cells. ICl was determined in ADPKD cell monolayers
mounted in Ussing chambers. (a) A representative trace where
5,6-dichloro-1-ethyl-1,3-dihydro-2H-benzimidazol-2-one (DCEBIO)
(10mM) was added to the media bathing the basolateral surface
of the monolayers. (b) Summary data showing the effect of
TRAM-34 and bumetanide on DCEBIO-stimulated ICl current.
Currents were recorded after 10–15 min of TRAM-34 or
bumetanide application.
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stimulation with 8-Br-cAMP, as previously described
(Figure 9).35 8-bromo-cAMP (8-Br-cAMP) stimulated the
proliferation of ADPKD but not NHK cells, as previously
described.35 However, proliferation was not inhibited by
TRAM-34, indicating that KCa3.1 does not play a role in the
proliferation of these cells at least under the conditions tested.
DISCUSSION
On the basis of a number of deregulated signaling pathways
that have been identified in ADPKD mutant renal epithelia,
several new pharmacological targets have emerged that have the
potential to slow the progressive decline in renal function in
ADPKD. Potential treatments include V2 receptor antagonists,
rapamycin, CDK2, and CFTR inhibitors.5,14,15,36 Our findings
demonstrate that KCa3.1 channels play an important role in
CFTR-stimulated Cl secretory flux in ADPKD mutant renal
epithelia, suggesting that KCa3.1 may constitute another
promising target to slow disease progression.
Several lines of evidence indicate that KCa3.1 is the
primary Kþ channel responsible for Cl secretion in ADPKD
mutant renal epithelia. First, KCa3.1 mRNA and KCa3.1
currents are present in primary human renal epithelia cells
and cyst-lining epithelial cells isolated from ADPKD patients.
Second, inhibition of KCa3.1 channel activity with TRAM-34
blocked the Cl secretion by normal and cyst-derived cell
monolayers. At the concentrations used, TRAM-34 has been
shown to be a specific inhibitor of KCa3.1, and thus it is
unlikely that TRAM-34 inhibits ICl by an effect that is
independent of KCa3.1.24 Third, the findings that transfec-
tion of an siRNA to KCa3.1, or overexpression of MTMR6, a
PI(3)P phosphatase that we have shown specifically inhibits
KCa3.1,31 also inhibit ICl in MDCK cells, provide additional
independent methods whereby inhibiting KCa3.1 blocks Cl
secretion. Fourth, DCEBIO, a direct activator of KCa3.1,
stimulates ICl in these cells.
KCa3.1 is an intermediate conductance Ca2þ -activated
Kþ channel. The regulation of these channels is complex and
a number of signaling molecules have been shown to be
required for KCa3.1 channel activation. In addition to
requiring calcium, KCa3.1 channels also require PI(3)P, and
direct phosphorylation on histidine 358 in its C terminus by
nucleoside diphosphate kinase B for activation.30,31,37 Other
studies have demonstrated roles for cAMP and PKA in
KCa3.1 channel activation.21,22 The role of cAMP in the
activation of KCa3.1 is of importance, as a number of studies
have shown that cAMP is elevated in the PKD kidneys.2,5 Our
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Figure 6 | TRAM-34 inhibits cyst formation by MDCK cells in
collagen gels in cell culture. MDCK cells were grown in collagen
gel matrix containing forskolin (10 mM). TRAM-34 (2 mM) or
glibencalmide (100 mM) was added on day 6 after plating and
(a–d) cysts were photographed on day 16. (e) Data represent
mean±s.e. of the number of cysts per 24 wells.
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Figure 7 | TRAM-34 inhibits cyst formation by ADPKD cells in
collagen gels in cell culture. ADPKD cells were grown in collagen
gel matrix containing EGF (25 ng ml1) and forskolin (10mM). On
day 6, TRAM-34 (2 mM) was added and (a) cyst number and (b) cyst
size were assessed on day 16. Cyst size was assessed using an
ocular scale in which one division¼ 25mm at original
magnification  40 as described.28 Cysts X100mm were clearly
identified and were counted.
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finding that KCa3.1 current is increased in MDCK and
ADPKD cells stimulated with forskolin/IBMX indicates that
cAMP and PKA could also contribute to Cl secretion by
direct activation of KCa3.1. Consistent with this idea,
stimulation of ADPK cells with forskolin/IBMX resulted in
the hyperpolarization of the cell membrane potential, which
would function to increase the electrical driving force for Cl
secretion in a manner similar to DCEBIO.
The importance of cAMP in the pathogenesis of polycystic
diseases of the kidney has been well established. Inhibitors of
the V2 receptor lower renal epithelial cAMP levels and halt
the development of renal cysts in animal models of PKD.32,36
However, although signaling via V2 receptors is a major
pathway to increase cAMP in renal epithelia in ADPKD, a
number of V2 receptor-independent pathways also contri-
bute to the increase in renal cAMP levels,2,5 including an
endogenous forskolin-like molecule that accumulates within
cyst fluid.38 Our data suggest that direct inhibitors of KCa3.1,
by blocking Cl secretion by cAMP that is generated via V2
receptor-independent pathway, may act synergistically with
Control MTMR6(PD)
MTMR6(PD)
MT
MR
6(P
D)
MTMR6(WT)
MTMR6(WT)
MTMR6
MT
MR
6(W
T)
35
30
25
20
15
10
5
0
Control MTMR6(PD) MTMR6(WT)Control
Co
ntr
ol
∗
∗
IB with anti-flag
N
o.
 
o
f c
ys
ts
∆N
or
m
a
liz
e
d 
I sc
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1000 µm
Figure 8 | Overexpression of MTMR6(WT), but not MTMR6(PD), in MDCK cells inhibits ICl and cyst formation in collagen gels. Stable
pools of MDCK cells infected with vector control, Flag-tagged-MTMR6(PD), or Flag-tagged-MTMR6(WT) were generated and plated in
collagen gels. (a–c) Photographs of representative cysts on day 16 of culture of (a) MDCK control cells, (b) MDCK cells overexpressing
MTMR6(PD), and (c) MDCK cells overexpressing MTMR6(WT). (d) Data represent mean±s.e. of the number of cysts per well. (e) ICl was
normalized to the stable forskolin/IBMX-stimulated current (n¼ 8 per cell). (f) Anti-Flag western blot of cell lysates demonstrating equal
levels of expression of MTMR6(WT) and MTMR6(PD).
180
160
140
120
100
80
H-89
cAMP
TRAM-34 (µM)
Ce
ll p
ro
life
ra
tio
n,
 %
+
+ + + + + + + +
0.01 0.1 0.5 1 2 5 10
Figure 9 | TRAM-34 does not inhibit the proliferation of
ADPKD cells. ADPKD cells were seeded into 96-well plates,
serum-starved for 24 h, and treated with 100 mM 8-Br-cAMP (cAMP)
in the absence or presence of various concentrations of TRAM-34.
Cell number was determined after 48 h using the Promega Cell
titer 96 MTT Assay. Bars represent the mean±s.e. normalized to
the untreated control group.
746 Kidney International (2008) 74, 740–749
o r i g i n a l a r t i c l e M Albaqumi et al.: KCa3.1 regulation of the CFTR channel
V2 receptor antagonists to inhibit cyst growth in patients
with ADPKD. KCa3.1 blockers may also be beneficial in
combination with antiproliferative agents that are currently
being considered to treat patients with ADPKD, such as
rapamycin, or inhibitors of CDKs or the RAS–MAPK
pathway. Combination therapy may provide a means to
target both the increase in cell proliferation that gives rise to
cysts, as well as the subsequent expansion of renal cysts that
results from the secretion of salt and water into the cyst
lumen. Direct inhibitors of KCa3.1 are already in phase 3
clinical trials for sickle cell disease. ICA17043, an inhibitor of
KCa3.1 developed by Icagen (Durham, NC, USA), is
extremely well tolerated without significant side effects.
Thus, if inhibitors of KCa3.1 are found to be effective in
animal models of PKD, these drugs may move rapidly into
clinical trial in ADPDK patients.
MATERIALS AND METHODS
Cells and cell culture
Type I MDCK epithelial cells were a generous gift from Dr Michael
Welsh (University of Iowa, Iowa City, IA, USA). The cells were
cultured in media containing a 1:1 mixture of Dulbecco’s modified
Eagle medium and Ham’s F12 nutrient medium supplemented with
10% fetal bovine serum (FBS) at 37 1C in a humidified atmosphere
of 5% CO2.
Primary cultures of NHK and ADPKD cells were generated by
the PKD Biomaterial Core at the University of Kansas Medical
Center (KUMC), as previously described.4,6,35 Briefly, primary cell
cultures were derived from normal regions of nephrectomy speci-
mens, confirmed by histological examination, or surface cysts of
ADPKD kidneys. These cell lines have characteristics of collecting
duct cells, in that they stain positive for cytokeritin and Dolichus
bifllorus agglutinin. The studies presented are representative of
similar results obtained from cell cultures isolated from three
patients. Cells were maintained in a 1:1 mixture of Dulbecco
modified Eagle’s medium and Ham F12 supplemented with 5%
FBM, 110 IU ml1 penicillin G, 0.1 mg ml1 streptomycin, and
5 mg ml1 insulin, 5 mg ml1 transferrin, and 5 ng ml1 sodium
selenite. Cells were used only up to passage 3.
Silencing of KCa3.1 in MDCK cells
MDCK cells were transfected with a SMART pool reagent
(combination of four individual siRNAs) to human KCNN4 obtai-
ned from Dharmacon using Fugene 6 (Roche, Nutley, NJ, USA). The
sequence of the siRNA’s used are as follows: siRNA1, 50-CAUCGGC
GCUCUCAAUCAAUU-30 (sense sequence) and 50-PUUGAUUGAG
AGCGCCGAUGUU-30 (anti-sense sequence); siRNA2, ACAAGAAG
CCUGGAUGUUCUU-30 (sense sequence) and 50-PGAACAUCCAG
GCUUCUUGUUU-30 (anti-sense sequence); siRNA3, CCGAGAGG
CAGGCUGUUAAUU-30 (sense sequence) and 50-PUUAACAGCCU
GCCUCUCGGUU-30 (anti-sense sequence); siRNA4, GCACUGGA
GUCAUGGGUGUUU-30 (sense sequence) and 50-PACACCCAUGA
CUCCAGUGCUU-30 (anti-sense sequence).
Ussing chamber experiments
MDCK, NHK, and ADPKD cells were seeded directly onto
permeable filter supports (Millicell-PCF culture plate inserts,
0.4mm pore size, 12 mm diameter, Millipore, Billerica, MA, USA;
Fisher Scientific, Pittsburgh, PA, USA) at a density of 2.5 105 cells
per well. Cells were studied on average 10 days after plating
when the transepithelial resistance (Rt) was between 3 and 5 kOhm
for MDCK cells, and between 500 and 1000 Ohm for primary
human epithelial cells. Cells were then mounted in modified
Ussing chambers (model U-2500; Harvard Apparatus Ltd). ICl was
determined at a transepithelial voltage of 0 mV in a basolateral
and apical membrane solutions that contained in the following
(mmol l1): 140 NaCl, 5 KCl, 0.36 K2HPO4, 0.44 KH2PO4, 1.3
CaCl2, 0.5 MgCl2, 10 HEPES (4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid), and 4.2 NaHCO3, pH 7.2 with Tris ([Cl
],
149 mmol l1); osmolarity, 292 mosM. The short-circuit current
(Isc) and the transepithelial resistance were measured with a dual
epithelial voltage-clamp apparatus (Warner Instrument, Hamden,
CT, USA), as described previously.8,39 Data were analyzed using
AxoScope data acquisition and analysis software (version 8.2, Axon
Instruments Inc., Union City, CA, USA). The change in Isc (DIsc)
induced by forskolin/IBMX or DCEBIO was expressed as the
difference from the baseline and was normalized to the stable
forskolin/IBMX or DCEBIO-stimulated current.
To test whether TRAM-34 had a direct effect on Cl channels
located in the apical membrane, the basolateral membrane was
permeabilized with nystatin (0.36 mg ml) and inserts were mounted
in the basolateral solution described above. The apical solution was
identical to that of the basolateral solution, with the exception that
in the apical solution 133.3 mmol l1 Na gluconate þ 2.5 mmol l1
NaCl, and 5 mmol l1 Kþ gluconate replaced 140 mmol l1 NaCl
and 5 mmol l1 KCl, respectively, to give a Cl concentration of
14.8 mmol l1 (osmolarity, 282±0.3 mosM; N¼ 9). This change in
composition of the bathing solution caused a Cl concentration
gradient from basolateral to apical solution.
To compensate for the Ca2þ buffering capacity of gluconate, the
Ca2þ concentration was increased to 5.7 mmol l1 in the apical
solution. All solutions were maintained at 37 1C and equilibrated
with 95% O2 and 5%CO2.
EM measurements with DiBAC4(3)
Cell membrane potential was measured as previously described.25
Changes in membrane potential in ADPKD cells were measured using
the fluorescent dye DiBAC4(3). Briefly, ADPKD cells were incubated
with 1mM of DiBAC4(3) for 30 min. EM was measured before and after
stimulation with forskolin/IBMX by measuring fluorescence above
520 nm following excitation at 488 nm. Cells were analyzed by laser
confocal microscopy (Leica Microsystmes, Allendale, NJ, USA)
equipped with 488 nm laser using a  63 oil objective. Images were
obtained every 5 s. Background fluorescence obtained from regions
containing no cells was digitally subtracted from each image. Data are
represented as F/F0, with F representing fluorescence values at different
time points, and F0 representing cellular fluorescence at time zero.
Cyst growth in collagen gel
MDCK, NHK, and ADPKD cells were plated in collagen and
stimulated with forskolin (10 mmol l1) as described by Li et al.8
Briefly, 800 cells were mixed with 0.4 ml of ice-cold PureCol collagen
(3.0 mg ml1 collagen; Inamed Biomaterials, Fremont, CA, USA)
supplemented with 10% (v/v) 10 minimum essential medium,
10 mmol l1 HEPES, 27 mmol l1 NaHCO3, 100 U ml
1 penicillin,
and 100mg ml1 streptomycin (pH 7.4 with NaOH) and plated into
24-well plates. After gelation, forskolin (10 mmol l1) was added to
each well of the 24-well plate. Plates were maintained at 37 1C in a
humidified atmosphere of 5% CO2, and media containing forskolin
were changed every 2 days. To assess the effect of TRAM-34 on cyst
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growth, TRAM-34 was added on day 1 or day 10 after stimulation
with forskolin and cyst formation was assessed on day 16.
Cyst number and volume measurements
On day 16 of culture, the 24-well plate was placed on the stage of an
inverted microscope and, using  40, the number of cysts in each
well was counted, and the diameter of each cyst was measured using
an ocular scale in which one division¼ 25 mm at  40. Only cysts
larger than 100 mm were clearly identified and counted.
Cell proliferation assays
Cell proliferation was determined as described previously.12,35
Briefly, 4000 cells were seeded into 96-well plates in Dulbecco’s
modified Eagle medium/F12 medium containing 1% FBS and
insulin/transferrin/selenium. After 24 h, cells were placed in media
containing 0.002% FBS and treated with control media or 100 mM
8-Br-cAMP in the presence or absence of various concentrations of
TRAM-34. Proliferation was assessed 72 h after treatment using the
Promega Cell titer 96 MTT Assay.
Reverse transcription-PCR
Total RNA was isolated from MDCK, NHK, and ADPKD cells, and
KCa3.1 was amplified using primers specific to canine KCa3.1 for
MDCK cells (forward: 50-GAACAAGTGAATTCCATGGT-30 and
backward: 50-CTATGTGGCCTCCTGGATG-30) or using primers
specific to human KCa3.1 for NHK, for and PKD/ cells (forward
50-ACTCGCAGGAAGGAGTCTCA-30 and backward: 50-TGCTAAG
CAGCTCAGTCAGG-30) as described.30,31
Overexpression of MTMR6(WT) and MTMR6(PD) in MDCK cells
MDCK cells were infected with a VSV-G-pseudotyped HIV-derived
lentivirus-expressing IRES-CD24, which has previously been
described,40 either alone (control) or containing the MTMR6(WT)
or MTMR6 (PD) cDNAs.30,31 Infected CD24 MDCK cells were
purified using biotin-conjugated anti-CD24 antibodies followed by
strepavidin-conjugated magnetic affinity cell sorting beads according
to the manufacturer’s protocol (Miltenyi Biotech, Auburn, CA, USA).
Greater than 85% of purified cells were HSA-positive following
purification as assessed by fluorescence-activated cell sorter.
Whole-cell patch clamp
Whole-cell patch clamp experiments were performed on MDCK,
NHK, and ADPKD cells at room temperature using a pipette
solution containing 145 mM Kþ aspartate, 10 mM K2EGTA, 8.5 mM
CaCl2, 2.0 mM MgCl2, and 10 mM HEPES (pH 7.2, 290–310 mosM),
with a calculated free [Ca2þ ]i of 1 mM. To eliminate native chloride
currents from the cells, sodium aspartate Ringer solution (160 mM
Naþ aspartate, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES
(pH 7.4), 290–310 mosM) was used as an external solution. Briefly,
current–voltage (I–V) relationships were measured using ramp
voltage clamp protocols (at 15 s intervals) from a holding potential
of 80 to 120 mV, followed by ramp depolarization to þ 60 mV
(symmetrical ramp rate of 0.18 mV ms1). The I–V relationship was
obtained by plotting the current during the depolarizing ramp phase
as a function of the corresponding voltage. Membrane currents were
filtered (3 dB at 1 kHz) and digitized at 10 kHz (pClamp 9.2 with
Digidata 1200 ADC interface; Axon Instruments). Whole-cell
current density was expressed as pA/pF.
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